ZUG, Switzerland and BOSTON — February 12, 2026 — Leads & Copy — CRISPR Therapeutics (Nasdaq: CRSP) has released its financial results for the fourth quarter and full year, which ended December 31, 2025.
The company’s net loss for the fourth quarter of 2025 was $130.6 million, compared to a net loss of $37.3 million for the same period in 2024. For the full year 2025, the net loss was $581.6 million, compared to $366.3 million in 2024.
According to Dr. Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics, the company is making progress across its pipeline. He cited advances across multiple clinical and preclinical programs, including data from zugo-cel in autoimmune disease and oncology, global uptake of CASGEVY, developments in the in vivo liver editing portfolio, and momentum in the siRNA collaboration with Sirius Therapeutics.
Key Highlights:
CASGEVY: The gene-edited cell therapy, CASGEVY, is approved in multiple countries for patients 12 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). Fourth quarter 2025 revenue for CASGEVY was $54 million, and full year 2025 revenue was $116 million. 64 patients received infusions of CASGEVY during the year, including 30 in the fourth quarter. 147 people with SCD or TDT initiated the treatment process with their first cell collection during the year.
Patient initiations and first cell collections increased nearly three-fold in 2025 compared to 2024. Access to CASGEVY has expanded, with approximately 90% of patients in the U.S. having reimbursed access as of year-end. Reimbursement is also available in the U.K., Italy, Austria, Denmark, Luxembourg, KSA, the Kingdom of Bahrain, the UAE, and Kuwait. Scotland secured reimbursed access for eligible patients with SCD in January 2026.
Positive pediatric data from pivotal studies in children ages 5-11 years with SCD or TDT were presented at the American Society of Hematology (ASH) annual meeting in December 2025. Global regulatory submissions in this age group are expected to begin in the first half of 2026. The FDA awarded a Commissioner’s National Priority Voucher for this pediatric submission.
CRISPR Therapeutics is advancing its in vivo hematopoietic stem cell editing approach utilizing lipid nanoparticle (LNP)-mediated delivery through preclinical studies.
In Vivo Liver Editing: CRISPR Therapeutics is advancing its in vivo gene editing programs. The company continues to advance CTX310, targeting angiopoietin-related protein 3 (ANGPTL3), in Phase 1b clinical trials, prioritizing development in severe hypertriglyceridemia (sHTG) and refractory hypercholesterolemia, with an update expected in the second half of 2026.
The company is advancing its next-generation LPA program, CTX321, which incorporates an updated guide RNA that demonstrates approximately two-fold greater potency in preclinical testing. CTX321 is currently in IND/CTA-enabling studies, with an Lp(a) program update expected in 2026.
CRISPR Therapeutics is advancing several preclinical in vivo gene editing candidates, including CTX460, targeting SERPINA1 for the treatment of alpha-1 antitrypsin deficiency (AATD), with a clinical trial expected in mid-2026, and CTX340, targeting angiotensinogen (AGT) for refractory hypertension, with a clinical trial expected in the first half of 2026.
siRNA-based Programs: CRISPR Therapeutics’ small interfering RNA (siRNA)-based portfolio includes clinical-stage programs in cardiovascular and thromboembolic diseases, developed with Sirius Therapeutics. CTX611 (SRSD107), a long-acting siRNA targeting Factor XI (FXI), is in an ongoing Phase 2 clinical trial in patients undergoing total knee arthroplasty (TKA), with an update expected in the second half of 2026. CRISPR Therapeutics is expected to lead global Phase 3 development of CTX611, with Sirius Therapeutics responsible for development activities in greater China.
Autoimmune Disease and Immuno-Oncology: Zugocabtagene geleucel (zugo-cel; formerly CTX112) continues to advance in clinical trials for autoimmune disease and hematologic malignancies, with updates expected in the second half of 2026.
Regenerative Medicine: CRISPR Therapeutics continues to advance its regenerative medicine portfolio, including CTX213, a deviceless beta cell replacement product candidate for the treatment of Type 1 diabetes.
Financial Results: Cash, cash equivalents, and marketable securities were $1,975.8 million as of December 31, 2025, compared to $1,903.8 million as of December 31, 2024. R&D expenses were $83.5 million for the fourth quarter of 2025, compared to $71.7 million for the fourth quarter of 2024. General and administrative expenses were $18.4 million for the fourth quarter of 2025, compared to $18.1 million for the fourth quarter of 2024. Collaboration expense, net, was $53.7 million for the fourth quarter of 2025, compared to $10.4 million for the same period in 2024.
Upcoming Events: The Company will present at Citi’s 2026 Virtual Oncology Leadership Summit on February 18, 2026, TD Cowen 46th Annual Health Care Conference on March 2, 2026, and Leerink Partners Global Healthcare Conference on March 11, 2026.
CASGEVY and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.
CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.
Source: CRISPR Therapeutics
